{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:48:59Z","timestamp":1770907739736,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T00:00:00Z","timestamp":1501804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.ijrobp.2017.07.041","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T02:47:41Z","timestamp":1501642061000},"page":"1234-1242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Phase 1\/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer"],"prefix":"10.1016","volume":"99","author":[{"given":"Miguel","family":"Reis Ferreira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atia","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Truelove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"McNair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris C.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Huddart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Bidmead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ros","family":"Eeles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"van As","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vibeke N.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Dearnaley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2017.07.041_bib1","unstructured":"NCCN clinical practice guidelines in oncology (NCCN guidelines) for prostate cancer. Version 1.2016. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed January 15, 2017."},{"key":"10.1016\/j.ijrobp.2017.07.041_bib2","unstructured":"Cancer Research UK. Prostate cancer statistics\u2014key facts. Available\u00a0at: www.cancerresearchuk.org\/health-professional\/prostate-cancer-statistics. Accessed March 23,\u00a02017."},{"key":"10.1016\/j.ijrobp.2017.07.041_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrurol.2015.25","article-title":"Radiotherapy for high-risk prostate cancer","volume":"12","author":"Mohiuddin","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib4","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nrurol.2015.283","article-title":"Prostate cancer: Elective pelvic nodal radiotherapy: Is the jury still out?","volume":"13","author":"Crook","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0360-3016(00)00653-2","article-title":"Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer","volume":"48","author":"Nutting","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib7","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(06)70904-4","article-title":"Image-guided radiotherapy: Rationale, benefits, and limitations","volume":"7","author":"Dawson","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s00066-014-0806-y","article-title":"Comparing morbidity and cancer control after 3D-conformal (70\/74 Gy) and intensity modulated radiotherapy (78\/82 Gy) for prostate cancer","volume":"191","author":"Dolezel","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3857\/roj.2014.32.3.179","article-title":"Long-term tolerance and outcomes for dose escalation in early salvage post-prostatectomy radiation therapy","volume":"32","author":"Safdieh","year":"2014","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib10","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2147\/OTT.S65238","article-title":"Long-term outcomes from dose-escalated image-guided intensity-modulated radiotherapy with androgen deprivation: Encouraging results for intermediate- and high-risk prostate cancer","volume":"7","author":"Wilcox","year":"2014","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib11","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/bjc.2013.394","article-title":"Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: Long-term follow-up","volume":"109","author":"Creak","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijrobp.2008.10.050","article-title":"Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer","volume":"75","author":"McCammon","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0360-3016(94)90138-4","article-title":"Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer","volume":"28","author":"Roach","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2003.09.004","article-title":"Clinical implementation of dynamic and step-and-shoot IMRT to treat prostate cancer with high risk of pelvic lymph node involvement","volume":"70","author":"Adams","year":"2004","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1120\/jacmp.v3i4.2551","article-title":"IMRT clinical implementation: Prostate and pelvic node irradiation using Helios and a 120-leaf multileaf collimator","volume":"3","author":"Clark","year":"2002","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib16","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0360-3016(95)90159-0","article-title":"LENT SOMA scales for all anatomic sites","volume":"31","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib18","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/00005650-199807000-00007","article-title":"The UCLA Prostate Cancer Index: Development, reliability, and validity of a health-related quality of life measure","volume":"36","author":"Litwin","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ijrobp.2016.11.008","article-title":"Acute and late adverse events associated with radical radiation therapy prostate cancer treatment: A systematic review of clinician and patient toxicity reporting in randomized controlled trials","volume":"97","author":"Holch","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0167-8140(01)00429-7","article-title":"Consequential late effects in normal tissues","volume":"61","author":"D\u00f6rr","year":"2001","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib21","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ijrobp.2013.07.041","article-title":"Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial","volume":"87","author":"Michalski","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib22","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00432-014-1813-1","article-title":"High dose versus conventional dose in external beam radiotherapy of prostate cancer: A meta-analysis of long-term follow-up","volume":"141","author":"Hou","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib23","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib24","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.ijrobp.2015.09.006","article-title":"Survival outcomes of whole-pelvic versus prostate-only radiation therapy for high-risk prostate cancer patients with use of the National Cancer Data Base","volume":"93","author":"Amini","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib25","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","article-title":"Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: Data from patients in the control arm of the STAMPEDE trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/1745-6215-12-255","article-title":"Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): Study protocol for a randomized controlled trial","volume":"12","author":"Lips","year":"2011","journal-title":"Trials"},{"issue":"Suppl. 2","key":"10.1016\/j.ijrobp.2017.07.041_bib27","first-page":"15","article-title":"The present and future of biomarkers in prostate cancer: Proteomics, genomics, and immunology advancements","volume":"8","author":"Gaudreau","year":"2016","journal-title":"Biomark Cancer"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib28","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib29","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/ng.3020","article-title":"A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1","volume":"46","author":"Fachal","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.ijrobp.2017.07.041_bib30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.radonc.2011.10.022","article-title":"Parameters for the Lyman Kutcher Burman (LKB) model of Normal Tissue Complication Probability (NTCP) for specific rectal complications observed in clinical practise","volume":"102","author":"Gulliford","year":"2012","journal-title":"Radiother Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617336556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617336556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T20:28:55Z","timestamp":1535574535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301617336556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0360301617336556"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.07.041","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1\/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.07.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}